LEADER 04444nam  2200601Ia 450 
001 9910877376403321
005 20200520144314.0
010   $a1-282-33160-4
010   $a9786612331602
010   $a1-4443-0846-7
010   $a1-4443-0847-5
035   $a(CKB)1000000000807261
035   $a(EBL)547043
035   $a(SSID)ssj0000310227
035   $a(PQKBManifestationID)11239011
035   $a(PQKBTitleCode)TC0000310227
035   $a(PQKBWorkID)10286712
035   $a(PQKB)11109624
035   $a(MiAaPQ)EBC547043
035   $a(OCoLC)476315063
035   $a(PPN)194581497
035   $a(EXLCZ)991000000000807261
100   $a20090202d2009      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 00$aStaphylococci in human disease /$fedited by Kent B. Crossley ... [et al.]
205   $a2nd ed.
210   $aChichester, West Sussex ;$aHoboken, NJ $cWiley-Blackwell$d2009
215   $a1 online resource (647 p.)
300   $aDescription based upon print version of record.
311   $a1-4051-6332-1 
320   $aIncludes bibliographical references and index.
327   $aStaphylococci inHuman Disease; Contents; Contributors; Preface to the Second Edition; Section IThe Organisms; Biology and Taxonomy; Chapter 1The Biology of Staphylococci; Chapter 2Genomics of the Staphylococci; Chapter 3Evolution and Taxonomyof Staphylococci; Chapter 4Molecular Basis of Pathogenicity; Chapter 5Adaptation to Stress: Biofilms andSmall-colony Variants; Chapter 6Exotoxins; Chapter 7Host Defense Against StaphylococcalInfection; Antimicrobial Resistance inStaphylococci; Chapter 8Resistance to b -Lactam Antibiotics; Chapter 9Resistance to Glycopeptides
327   $aChapter 10Resistance to Other AgentsLaboratory Studies; Chapter 11Issues in the Identification andSusceptibility Testing of Staphylococci; Section IIEpidemiology of StaphylococcalInfection; Chapter 12Colonization with Staphylococcusaureus and the Role of Colonizationin Causing Infection; Chapter 13Epidemiology of Community-associatedStaphylococcus aureus Infections; Chapter 14Epidemiology of Healthcare-associatedStaphylococcus aureus Infections; Chapter 15Epidemiology of Coagulase-negativeStaphylococci and Infections Causedby these Organisms; Section IIIDiseases Caused by Staphylococci
327   $aChapter 16Staphylococcus aureus Bacteremiaand EndocarditisChapter 17Surgical-site Infections andSurgical Prophylaxis; Chapter 18Infections of Intravascular Cathetersand Vascular Devices; Chapter 19Skin and Soft Tissue Infections; Chapter 20Central Nervous System Infections; Chapter 21Diseases of the Eye; Chapter 22Osteomyelitis and Other Bone andJoint Infections; Chapter 23Staphylococcal Pneumonia; Chapter 24Urinary Tract Infections; Chapter 25Toxic Shock Syndrome; Chapter 26Toxin-mediated Syndromes; Chapter 27Staphylococcal Diarrhea andEnterocolitis
327   $aChapter 28Infections in ImmunocompromisedPatientsChapter 29Clinical Manifestations of Community-acquiredMRSA Infections; Section IVPrevention and Treatment ofStaphylococcal Infections; Chapter 30Elimination of Staphylococcus aureusCarriage: Importance and Strategies; Chapter 31Treatment of Staphylococcal Infection; Chapter 32Vaccine-based Strategies for Preventionof Staphylococcus aureus Infection; Index; Plates
330   $aStaphylococci remain the most important cause of hospital-acquired infections in the U.S. and MRSA has become the most common cause of skin and soft tissue infection in many parts of the world. There is now a much greater understanding of the physiology and evolution of the staphylococci and this new edition reflects the rapid advancements in knowledge about this pathogen and provides a comprehensive review from both clinical and basic science perspectives. The first section addresses the basic biology of the staphylococci, their molecular genetics, host defenses and host evasion, virulenc
606   $aStaphylococcal infections
606   $aGram-positive bacterial infections
615  0$aStaphylococcal infections.
615  0$aGram-positive bacterial infections.
676   $a616.9297
701   $aCrossley$b Kent B$01755514
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910877376403321
996   $aStaphylococci in human disease$94192313
997   $aUNINA